Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-12-28

Clinical Trial Update: Neoadjuvant Carboplatin in Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating neoadjuvant carboplatin in triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CARBOPLATIN (Carboplatin)

Snippet

Sponsor: Barretos Cancer Hospital | Conditions: BRCA1 Hereditary Breast and Ovarian Cancer Syndrome | Phase 2 | Status: COMPLETED